⚕️ The information below is for educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
Semaglutide (brand names: Ozempic, Wegovy, Rybelsus) and liraglutide (Saxenda, Victoza) have generated more myths, misconceptions, and outright misinformation in India than almost any medication in recent memory. WhatsApp forwards, Instagram reels, and overconfident online forums have created a fog of confusion.
This guide examines nine of the most common myths circulating in Indian communities — and what the actual clinical evidence says.
Consult your healthcare provider before starting any medication.
Several factors make GLP-1 misinformation particularly persistent in India:
Verdict: Partially true, but deeply misleading
Yes, weight typically does return after stopping GLP-1 — studies show 60–70% of lost weight is regained within 1–2 years of stopping (STEP 1 trial extension, NEJM 2022). However, calling this a "shortcut" misunderstands the nature of obesity.
The full picture:
What this means for Indians: Work with your doctor on a long-term maintenance strategy. GLP-1 is most effective as part of a comprehensive plan — not a standalone quick fix.
Verdict: False for most people — one specific contraindication applies
This myth stems from a real but specific concern: thyroid C-cell tumours were observed in rodent studies with semaglutide. However:
The actual contraindication: GLP-1 medications are contraindicated if you have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2).
For everyone else, current evidence does not support cancer concern as a reason to avoid these medications. Pancreatitis (not cancer) remains a known rare risk — discussed with your doctor.
Verdict: Dangerous and likely counterfeit
India has seen a surge in counterfeit and substandard GLP-1 products:
Why this is dangerous:
Legitimate cost benchmarks in India (2024–2025):
If the price seems too good to be true, it is.
Verdict: False — major indications now include obesity
The landscape has evolved significantly since the first GLP-1 approvals:
Indian doctors increasingly prescribe these medications for weight management in patients without diabetes — a recognised, evidence-based practice.
Verdict: False — diet remains essential
GLP-1 medications reduce appetite and slow gastric emptying, but they do not:
Indian diet context: The average Indian diet is high in refined carbohydrates (white rice, maida, fried snacks) and low in protein. On a GLP-1 medication, this is particularly problematic — reduced appetite makes it easy to under-eat protein, leading to muscle loss alongside fat loss.
Minimum targets on GLP-1:
Verdict: Partially true but manageable — and not specific to semaglutide
"Ozempic face" refers to facial volume loss from rapid weight loss — it is not a specific drug effect. When you lose 10–20% body weight:
What the evidence shows:
Indian context: Darker skin types common in Indians have more natural collagen density, which may reduce the severity of this effect compared to what is widely reported in Western populations.
Verdict: False — GLP-1 medications have 15–20 years of evidence
The SELECT trial (2023) enrolled 17,604 participants and showed semaglutide reduced major cardiovascular events by 20% in people with obesity and established cardiovascular disease — even in those without diabetes. This is among the largest cardiovascular outcomes trials in history.
Verdict: Nuanced — discuss with your doctor and religious authority
This concern arises frequently in Indian communities:
Consult both your physician and your religious authority for guidance specific to your situation and belief system.
Verdict: False and potentially harmful
GLP-1 medications follow a strict titration protocol for good reason:
Standard semaglutide titration (weekly injection):
| Claim | Verdict |
|---|---|
| Weight returns when you stop | Largely true — long-term plan needed |
| Causes cancer | False — specific contraindications apply |
| Available cheap online | Dangerous — likely counterfeit |
| Only for diabetics | False — approved for obesity too |
| No need to change diet | False — diet is essential |
| Ozempic face is permanent | False — manageable and temporary |
| Too new to trust | False — 15–20 years of evidence |
| Vegetarians can't use it | Nuanced — discuss with your doctor |
| Higher dose = faster results | False — follow prescribed titration |
The most dangerous myth of all is that you can make informed decisions about prescription medications without professional guidance.
Consult your healthcare provider before starting any medication. This article is for informational purposes only and does not constitute medical advice.
